76.7 F
San Fernando
Saturday, Sep 23, 2023

Amgen, Bind Therapeutics End Collaboration

Amgen Inc. has opted out of a collaborative agreement with Bind Therapeutics Inc., a company developing tiny particles that adhere to medicines and help the drugs circulate longer in the bloodstream and enter cells. In December 2012, the Thousand Oaks pharmaceutical company entered into a 12-month agreement with Bind to combine its technology with an Amgen cancer drug. The agreement was extended until this month, but Bind announced both companies have decided to discontinue the arrangement. “The goal of this research collaboration was to optimize a specific therapeutic payload from Amgen. Despite achieving the objective of high tumor concentrations, the results were not sufficiently compelling to proceed forward,” Scott Minick, chief executive of Bind, said in a statement. In addition to its deal with Amgen, Bind has announced collaborations with Pfizer Inc., AstraZeneca and Roche. Since the announcement on July 2, Bind shares have lost $1.21 or 9.3 percent to close Monday at $11.68. Shares of Amgen have lost 82 cents or less than 1 percent to close at $120.16 on the Nasdaq.

Joel Russel
Joel Russel
Joel Russell joined the Los Angeles Business Journal in 2006 as a reporter. He transferred to sister publication San Fernando Valley Business Journal in 2012 as managing editor. Since he assumed the position of editor in 2015, the Business Journal has been recognized four times as the best small-circulation tabloid business publication in the country by the Alliance of Area Business Publishers. Previously, he worked as senior editor at Hispanic Business magazine and editor of Business Mexico.

Featured Articles

Related Articles